US FDA declines to approve Minerva Neurosciences' schizophrenia drug
Feb 27 (Reuters) - Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia. (Reporting by Pratik Jain in Bengaluru)